GlassScriptPhysician profile
Sally S Ball
NPI 1568441251
$6,652.86
in general payments reported to CMS, 2019-2025
49 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $644 · 2021: $1,122 · 2022: $1,637 · 2023: $1,465 · 2024: $831 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.68 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,027.42 | 2020-2024 | Injectafer |
| Pfizer INC. | $427.24 | 2019-2025 | |
| Lilly USA, LLC | $422.87 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $392.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $375.26 | 2021-2025 | Ubrelvy |
| Acadia Pharmaceuticals INC | $323.70 | 2019-2024 | Nuplazid |
| Glaxosmithkline, LLC. | $240.56 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $200.01 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $195.10 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $164.78 | 2020-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.32 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.90 | 2019-2024 | Xifaxan |
| Dexcom, INC. | $132.75 | 2024-2025 | Dexcom G6 Transmitter |
| Ucb, INC. | $114.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $91.89 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.